

1	Type of Issue (IPO/FPO)	IPO
2	Issue Size (Rs. Cr)	1,952.027*
	* As per Basis of Allotment	

3	Grade of issue alongwith name of the rating agency	
	Name	Not Applicable
	Grade	Not Applicable

4	Subscription Level (Number of times):	68.17
	*The above figure is after technical rejection and excludes anchor allotment	
	Source: Minutes of Basis of Allotment	

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	5.09%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (Sept 30, 2024)	6.87%
(iii) at the end of 1st FY (March 31, 2025)#	Not Available
(iv) at the end of 2nd FY (March 31, 2026)#	Not Available
(v) at the end of 3rd FY (March 31, 2027)#	Not Available

* As per the Basis of Allotment

QIB Holding not disclosed as reporting for relevant fiscal years have not been completed/ not publicly available

Source:

(1) Basis of Allotment

(2) Reported to the stock exchanges;

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Crore)

Parameters (Consolidated)	1nd FY (March 31, 2025)*	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

* Financials not disclosed as reporting for the fiscal year has not been completed / not publicly available

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.

The Shares have not been suspended or delisted.

Particulars	Status
(ii) at the end of 1nd FY (March 31, 2025)*	Not Applicable
(ii) at the end of 2nd FY (March 31, 2026)*	Not Applicable
(iii) at the end of 3rd FY (March 31, 2027)*	Not Applicable

* Trading status not disclosed as the relevant fiscal year has not been completed

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Mr. Samonnoi Banerjee	Resigned
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available

*Changes in Directors not disclosed as the relevant fiscal year has not been completed

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - Not Applicable
- (ii) Actual implementation - Not Applicable
- (iii) Reasons for delay in implementation, if any - Not Applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document (Rs. Crore)

Particulars	Amount
Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed	600.00
General corporate purposes	158.86
Total	758.86

(ii) Actual utilization (Rs. Crore)

Particulars	Amount proposed in the offer document	Amount utilized as on 30th Sept 2024	Unutilized amount as on 30th Sept 2024
Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed	600.00	600.00	0.00
General corporate purposes	158.86	159.04	0.00
Total	758.86	759.04	0.00

(iii) Reasons for deviation, if any - The main reason for increase in GCP spends is the interest income on fixed deposit received of Rs. 0.18 Crore

11 Comments of monitoring agency, if applicable

The utilization of the issuance proceeds is in line with the objects of the issue, however there is increase in GCP spends due to interest income on fixed deposit received of Rs. 0.18 Crore

12 Pricing Data

Issue Price (Rs.): 1,008
 Designated Stock Exchange: NSE
 Listing Date: 10-Jul-24

Price parameters	At close of listing day (Jul 10, 2024)	At close of 30th calendar day from listing day ⁽¹⁾	At close of 90th calendar day from listing day ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2025) ⁽³⁾			As at the end of 2nd FY after the listing of the issue (March 31, 2026) ⁽³⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2027) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	1,359.15	1,289.65	1,331.35	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A
Nifty 50	24,324.45	24,117.00	24,795.75	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A
Sectoral Index	N.A.	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website

(1) 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(2) 90th calendar day has been taken as listing date plus 89 calendar days, except where 90th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(3) Pricing data not disclosed as the relevant fiscal year has not been completed.

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document dated Jul 05, 2024	At the end of 1st FY (March 31, 2025)	At the end of 2nd FY (March 31, 2026)*	At the end of 3rd FY (March 31, 2027)*	
Diluted EPS (Rs.)⁽⁴⁾:	Issuer⁽¹⁾:	27.54	Not Available	Not Available	Not Available
	Peer Group⁽²⁾:				
	Dr. Reddy's Laboratories Limited	334.59	Not Available	Not Available	Not Available
	Cipla Limited	51.01	Not Available	Not Available	Not Available
	Alkem Laboratories Limited	150.19	Not Available	Not Available	Not Available
	Torrent Pharmaceuticals Limited	48.94	Not Available	Not Available	Not Available
	Mankind Pharma Limited	47.68	Not Available	Not Available	Not Available
	Abbott India Limited	565.28	Not Available	Not Available	Not Available
	J. B. Chemicals & Pharmaceuticals Limited	34.85	Not Available	Not Available	Not Available
	Industry Avg:	176.08	Not Applicable	Not Applicable	Not Applicable
P/E⁽⁵⁾	Issuer⁽¹⁾:	36.60 ⁽³⁾	Not Available	Not Available	Not Available
	Peer Group⁽²⁾:				
	Dr. Reddy's Laboratories Limited	17.93	Not Available	Not Available	Not Available
	Cipla Limited	30.10	Not Available	Not Available	Not Available
	Alkem Laboratories Limited	33.86	Not Available	Not Available	Not Available
	Torrent Pharmaceuticals Limited	57.74	Not Available	Not Available	Not Available
	Mankind Pharma Limited	45.30	Not Available	Not Available	Not Available
	Abbott India Limited	47.43	Not Available	Not Available	Not Available
	J. B. Chemicals & Pharmaceuticals Limited	50.49	Not Available	Not Available	Not Available
	Industry Avg:	40.41	Not Applicable	Not Applicable	Not Applicable
RoNW (%)⁽⁶⁾	Issuer⁽¹⁾:	16.87%	Not Available	Not Available	Not Available
	Peer Group⁽²⁾:				
	Dr. Reddy's Laboratories Limited	19.74%	Not Available	Not Available	Not Available
	Cipla Limited	15.43%	Not Available	Not Available	Not Available
	Alkem Laboratories Limited	17.41%	Not Available	Not Available	Not Available
	Torrent Pharmaceuticals Limited	24.15%	Not Available	Not Available	Not Available
	Mankind Pharma Limited	20.43%	Not Available	Not Available	Not Available
	Abbott India Limited	32.48%	Not Available	Not Available	Not Available
	J. B. Chemicals & Pharmaceuticals Limited	18.90%	Not Available	Not Available	Not Available
	Industry Avg:	21.22%	Not Applicable	Not Applicable	Not Applicable
NAV per share based on last balance sheet⁽⁷⁾	Issuer⁽¹⁾:	163.22	Not Available	Not Available	Not Available
	Peer Group⁽²⁾:				
	Dr. Reddy's Laboratories Limited	1693.75	Not Available	Not Available	Not Available
	Cipla Limited	330.78	Not Available	Not Available	Not Available
	Alkem Laboratories Limited	862.46	Not Available	Not Available	Not Available
	Torrent Pharmaceuticals Limited	202.57	Not Available	Not Available	Not Available
	Mankind Pharma Limited	233.73	Not Available	Not Available	Not Available
	Abbott India Limited	1740.71	Not Available	Not Available	Not Available
	J. B. Chemicals & Pharmaceuticals Limited	188.37	Not Available	Not Available	Not Available
	Industry Avg:	750.34	Not Applicable	Not Applicable	Not Applicable

Source: Prospectus

(1) The financial information for our Company is based on the Restated Consolidated Financial Information as at and for the financial year ended March 31, 2024

(2) The financial information for listed industry peers mentioned above is on a consolidated basis (except for Abbott India Limited, where financial information is available only on a standalone basis) and is sourced from the financial statements of the respective company for the financial year ended March 31, 2024 submitted to the Stock Exchanges

(3) P/E Ratio of the Company has been computed based on the Offer Price divided by the diluted EPS

(4) Diluted EPS for peers are sourced from the audited financial statements for the relevant year

(5) P/E Ratio has been computed based on the closing market price of equity shares on BSE Limited on June 21, 2024, divided by the Diluted EPS

(6) For listed peers, RoNW is computed as profit attributable to owners of the company divided by Total Equity attributable to the owners of the Company as on March 31, 2024

(7) Net Asset Value ("NAV") is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2024

* Not available as reporting for the relevant period has not been completed / not available publicly

14 Any other material information

Particulars	Date
Listing of equity shares of Emcure Pharmaceuticals Limited	10-Jul-24
Company, together with its subsidiary, Genova Biopharmaceuticals Limited ("Genova"), has entered into a Share Subscription and Shareholders' Agreement dated July 25, 2024 to acquire 26% shareholding in Sunsure Solarpark Twelve Private Limited (Emcure: 21.34%, Genova: 4.65%)	25-Jul-23
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2024	13-Aug-24
CRISIL Ratings Limited ("CRISIL"), has upgraded ratings on the bank loan facilities to AA-/Stable	13-Aug-24
CARE Ratings Limited ("CARE"), has upgraded ratings on the bank loan facilities to AA-/Stable	13-Aug-24
Emcure Pharmaceuticals signs agreement with Gilead for manufacture & global supply of Lenacapavir	3-Oct-24
Received RoC approval for incorporation of wholly owned subsidiary "Emcutix Biopharmaceuticals Limited"	3-Oct-24
Approval of Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2024	7-Nov-24
Resignation of Mr. Samonnoi Banerjee, NonExecutive and Non – Independent Director of the Company	23-Nov-24

Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com